
zzso zzso Millennium Pharmaceuticals, zzso Cambridge, MA, and Johnson & Johnson zzso Research & Development, zzso zzso zzso is a zzso zzso inhibitor developed specifically for use as an zzso zzso zzso of the zzso results in disruption of zzso mechanisms within the cell that can lead to cell zzso zzso first indication, for the treatment of relapsed myeloma in patients who have received at least two prior treatments and progressed on their previous treatment, was based in part on the magnitude of activity demonstrated in phase II zzso zzso is currently indicated for patients who have received at least one prior therapy in the United States and European Union, although patients in the European Union must have already undergone bone zzso transplantation or be zzso for the zzso A phase III trial demonstrated the superiority of zzso over high-dose zzso in response rate, time to zzso and survival in patients with myeloma who had relapsed after 1-3 prior zzso Clinical development is ongoing to investigate its activity as zzso and in combination regimens for the treatment of zzso lymphoma, solid tumors, and earlier presentations of zzso 

